Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Q2 net loss narrows to $38.3 million; FDA grants RMAT for miv-cel

Positive Impact 3 of 5 earnings Written later

Kyverna Therapeutics reported a second-quarter 2026 net loss of $38.3 million, or $0.63 per share, compared with a net loss of $42.1 million, or $0.97 per share, in the same quarter of 2025. The company had $199.4 million in cash, cash equivalents, and marketable securities at June 30, 2026, and reiterated that its operating runway extends into 2028.

Key points

  • Q2 2026 net loss of $38.3 million, or $0.63 per share, versus $42.1 million, or $0.97 per share, in Q2 2025
  • R&D expenses were $24.8 million and G&A expenses were $14.8 million in the quarter
  • Cash, cash equivalents, and marketable securities of $199.4 million at June 30, 2026; runway into 2028
  • FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis; rolling BLA for stiff person syndrome expected to be completed in Q4 2026

The filing

CompanyKyverna Therapeutics, Inc. (KYTX)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:04 PM ET
Accession number0001193125-26-344572

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.